{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:24:24Z","timestamp":1790310264246,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.gene.2023.147179","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T11:24:36Z","timestamp":1673090676000},"page":"147179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family"],"prefix":"10.1016","volume":"857","author":[{"given":"Ioannis A.","family":"Voutsadakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2023.147179_b0005","doi-asserted-by":"crossref","unstructured":"Alcon, C., G\u00f3mez Tejeda Za\u00f1udo, J., Albert, R., Wagle, N., Scaltriti, M., Letai, A., Samitier, J., Montero, J., 2021. ER+ breast cancer strongly depends on MCL-1 and BCL-xL anti-apoptotic proteins. Cells 2021;10(7): 1659. doi: 10.3390\/cells10071659. PMID: 34359829; PMCID: PMC8304651.","DOI":"10.3390\/cells10071659"},{"issue":"2","key":"10.1016\/j.gene.2023.147179_b0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","article-title":"Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets","volume":"4","author":"Balko","year":"2014","journal-title":"Can. Discov."},{"issue":"2","key":"10.1016\/j.gene.2023.147179_b0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41419-017-0035-2","article-title":"MCL-1 is a prognostic indicator and drug target in breast cancer","volume":"9","author":"Campbell","year":"2018","journal-title":"Cell Death Dis."},{"issue":"D1","key":"10.1016\/j.gene.2023.147179_b0020","doi-asserted-by":"crossref","first-page":"D165","DOI":"10.1093\/nar\/gkab1113","article-title":"JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles","volume":"50","author":"Castro-Mondragon","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.gene.2023.147179_b0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Can. Discov."},{"issue":"4","key":"10.1016\/j.gene.2023.147179_b0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1439-0264.2012.01134.x","article-title":"BCL-2 family of proteins and mammary cellular fate","volume":"41","author":"Colitti","year":"2012","journal-title":"Anat. Histol. Embryol."},{"key":"10.1016\/j.gene.2023.147179_b0035","doi-asserted-by":"crossref","unstructured":"Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., Gr\u00e4f, S., Ha, G., Haffari, G., Bashashati, A., Russell, R., McKinney, S., METABRIC Group, Langer\u00f8d, A., Green, A., Provenzano, E., Wishart, G., Pinder, S., Watson, P., Markowetz, F., Murphy, L., Ellis, I., Purushotham, A., B\u00f8rresen-Dale, A.L., Brenton, J.D., Tavar\u00e9, S., Caldas, C., Aparicio, S., 2012. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486(7403): 346-352. doi: 10.1038\/nature10983. PMID: 22522925; PMCID: PMC3440846.","DOI":"10.1038\/nature10983"},{"issue":"5","key":"10.1016\/j.gene.2023.147179_b0040","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/sj.bjc.6605736","article-title":"BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received","volume":"103","author":"Dawson","year":"2010","journal-title":"Br. J. Can."},{"issue":"6","key":"10.1016\/j.gene.2023.147179_b0045","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Can. J. Clin."},{"issue":"Database issue","key":"10.1016\/j.gene.2023.147179_b0050","doi-asserted-by":"crossref","first-page":"D92","DOI":"10.1093\/nar\/gku1111","article-title":"The Eukaryotic Promoter Database: expansion of EPDnew and new promoter analysis tools","volume":"43","author":"Dreos","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"20","key":"10.1016\/j.gene.2023.147179_b0055","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.gene.2023.147179_b0060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/febs.15767","article-title":"The guardian's choice: how p53 enables context-specific decision-making in individual cells","volume":"289","author":"Friedel","year":"2022","journal-title":"FEBS J."},{"issue":"269","key":"10.1016\/j.gene.2023.147179_b0065","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"issue":"4","key":"10.1016\/j.gene.2023.147179_b0070","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/1078-0432.CCR-20-1720","article-title":"Genomic characterization of de novo metastatic breast cancer","volume":"27","author":"Garrido-Castro","year":"2021","journal-title":"Clin. Can. Res."},{"issue":"7866","key":"10.1016\/j.gene.2023.147179_b0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","article-title":"Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity","volume":"595","author":"Griffin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.gene.2023.147179_b0080","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","article-title":"Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer","volume":"19","author":"Gy\u0151rffy","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"5","key":"10.1016\/j.gene.2023.147179_b0085","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.gene.2023.147179_b0090","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.trecan.2021.08.002","article-title":"Tilting MYC toward cancer cell death","volume":"7","author":"Harrington","year":"2021","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.gene.2023.147179_b0095","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14656566.2021.1882421","article-title":"Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far","volume":"22","author":"Held","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.gene.2023.147179_b0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.gene.2023.147179_b0105","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3109\/0284186X.2011.653009","article-title":"Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy","volume":"51","author":"Larsen","year":"2012","journal-title":"Acta Oncol."},{"key":"10.1016\/j.gene.2023.147179_b0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf."},{"issue":"6","key":"10.1016\/j.gene.2023.147179_b0115","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/2159-8290.CD-21-0832","article-title":"Precision combination therapies based on recurrent oncogenic coalterations","volume":"12","author":"Li","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.gene.2023.147179_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.109087","article-title":"Histone methyltransferase SETDB1 inhibits TGF-\u03b2-induced epithelial-mesenchymal transition in pulmonary fibrosis by regulating SNAI1 expression and the ferroptosis signaling pathway","volume":"715","author":"Liu","year":"2022","journal-title":"Arch. Biochem. Biophys."},{"issue":"3","key":"10.1016\/j.gene.2023.147179_b0125","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2159-8290.CD-18-1151","article-title":"A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer","volume":"9","author":"Lok","year":"2019","journal-title":"Can. Discov."},{"issue":"15","key":"10.1016\/j.gene.2023.147179_b0130","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/onc.2015.287","article-title":"Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer","volume":"35","author":"Merino","year":"2016","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.gene.2023.147179_b0135","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol."},{"issue":"7418","key":"10.1016\/j.gene.2023.147179_b0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Network","year":"2012","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.gene.2023.147179_b0145","doi-asserted-by":"crossref","first-page":"jcs212563","DOI":"10.1242\/jcs.212563","article-title":"Re-inforcing the cell death army in the fight against breast cancer","volume":"131","author":"Oudenaarden","year":"2018","journal-title":"J. Cell Sci."},{"issue":"8","key":"10.1016\/j.gene.2023.147179_b0150","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1128\/MCB.20.8.2890-2901.2000","article-title":"17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence","volume":"20","author":"Perillo","year":"2000","journal-title":"Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.gene.2023.147179_b0155","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.gene.2023.147179_b0165","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.gene.2023.147179_b0170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.gene.2023.147179_b0175","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.21873\/anticanres.14486","article-title":"The future of ER+\/HER2- metastatic breast cancer therapy: beyond PI3K inhibitors","volume":"40","author":"Stravodimou","year":"2020","journal-title":"Antican. Res"},{"issue":"1","key":"10.1016\/j.gene.2023.147179_b0180","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13046-021-02157-5","article-title":"BH3-mimetics: recent developments in cancer therapy","volume":"40","author":"Townsend","year":"2021","journal-title":"J. Exp. Clin. Can. Res."},{"issue":"4706","key":"10.1016\/j.gene.2023.147179_b0185","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"issue":"25","key":"10.1016\/j.gene.2023.147179_b0190","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"OlympiA clinical trial steering committee and investigators. Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6220","key":"10.1016\/j.gene.2023.147179_b0195","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.gene.2023.147179_b0200","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ccr.2013.06.002","article-title":"Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer","volume":"24","author":"Vaillant","year":"2013","journal-title":"Can. Cell"},{"issue":"2","key":"10.1016\/j.gene.2023.147179_b0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/028418600430707","article-title":"Apoptosis and the pathogenesis of lymphoma","volume":"39","author":"Voutsadakis","year":"2000","journal-title":"Acta Oncol."},{"issue":"11","key":"10.1016\/j.gene.2023.147179_b0210","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.21873\/anticanres.11145","article-title":"Immune Blockade Inhibition in Breast Cancer","volume":"36","author":"Voutsadakis","year":"2016","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.gene.2023.147179_b0215","doi-asserted-by":"crossref","first-page":"315","DOI":"10.14701\/ahbps.2021.25.3.315","article-title":"Mutations of p53 associated with pancreatic cancer and therapeutic implications","volume":"25","author":"Voutsadakis","year":"2021","journal-title":"Ann. Hepatobiliary Pancreat. Surg."},{"key":"#cr-split#-10.1016\/j.gene.2023.147179_b0220.1","doi-asserted-by":"crossref","unstructured":"Voutsadakis, I.A., 2022. Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors. Gene 2022 Dec 30","DOI":"10.1016\/j.gene.2022.146881"},{"key":"#cr-split#-10.1016\/j.gene.2023.147179_b0220.2","doi-asserted-by":"crossref","unstructured":"847: 146881. doi: 10.1016\/j.gene.2022.146881. Epub 2022 Sep 11. PMID: 36100115.","DOI":"10.1016\/j.gene.2022.146881"},{"key":"10.1016\/j.gene.2023.147179_b0225","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.620089","article-title":"Senescence and apoptosis: architects of mammalian development","volume":"8","author":"Wanner","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.gene.2023.147179_b0230","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.18632\/oncotarget.2792","article-title":"Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?","volume":"6","author":"Williams","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.gene.2023.147179_b0235","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1541-7786.MCR-16-0280-T","article-title":"Key survival factor, Mcl-1, correlates with sensitivity to combined Bcl-2\/Bcl-xL blockade","volume":"15","author":"Williams","year":"2017","journal-title":"Mol. Can. Res."},{"issue":"2","key":"10.1016\/j.gene.2023.147179_b0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41419-017-0072-x","article-title":"Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers","volume":"9","author":"Williams","year":"2018","journal-title":"Cell Death Dis."},{"issue":"52","key":"10.1016\/j.gene.2023.147179_b0245","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.18632\/oncotarget.27070","article-title":"Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers","volume":"10","author":"Williams","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.gene.2023.147179_b0250","doi-asserted-by":"crossref","unstructured":"Winder, M.L., Campbell, K.J., 2022. MCL-1 is a clinically targetable vulnerability in breast cancer. Cell Cycle 2022 Mar 29: 1-17. doi: 10.1080\/15384101.2022.2054096. Epub ahead of print. PMID: 35349392.","DOI":"10.1080\/15384101.2022.2054096"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111923000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111923000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T16:59:02Z","timestamp":1759856342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111923000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":50,"alternative-id":["S0378111923000203"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2023.147179","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2023.147179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"147179"}}